{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:15:21Z","timestamp":1791018921196,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian Pediatr"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1007\/s13312-013-0284-9","type":"journal-article","created":{"date-parts":[[2013,11,18]],"date-time":"2013-11-18T07:26:53Z","timestamp":1384759613000},"page":"1033-1040","source":"Crossref","is-referenced-by-count":29,"title":["Newer anti-epileptic drugs"],"prefix":"10.1007","volume":"50","author":[{"given":"Satinder","family":"Aneja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvasini","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,19]]},"reference":[{"key":"284_CR1","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1212\/01.WNL.0000127773.72699.C8","volume":"62","author":"MT Mackay","year":"2004","unstructured":"Mackay MT, Weiss SK, Adams-Webber T, Ashwal S, Stephens D, Ballaban-Gill K, et al. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology. 2004; 62:1668\u20131681.","journal-title":"Neurology"},{"key":"284_CR2","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1212\/WNL.0b013e318259e2cf","volume":"78","author":"CY Go","year":"2012","unstructured":"Go CY, Mackay MT, Weiss SK, Stephens D, Adams-Webber T, Ashwal S, et al. Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2012;78:1974\u20131980.","journal-title":"Neurology"},{"key":"284_CR3","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1212\/WNL.57.8.1416","volume":"57","author":"RD Elterman","year":"2001","unstructured":"Elterman RD, Shields WD, Mansfield KA, Nakagawa J. Randomized trial of vigabatrin in patients with infantile spasms. Neurology. 2001;57:1416\u20131421.","journal-title":"Neurology"},{"key":"284_CR4","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1474-4422(05)70199-X","volume":"4","author":"AL Lux","year":"2005","unstructured":"Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, et al. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lancet Neurol. 2005;4:712\u2013717.","journal-title":"Lancet Neurol"},{"key":"284_CR5","first-page":"57","volume-title":"Acta Neurol Scand Suppl","author":"GT Plant","year":"2011","unstructured":"Plant GT, Sergott RC. Understanding and interpreting vision safety issues with vigabatrin therapy. Acta Neurol Scand Suppl. 2011:57\u201371."},{"key":"284_CR6","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1528-1167.2008.01988.x","volume":"50","author":"LJ Willmore","year":"2009","unstructured":"Willmore LJ, Abelson MB, Ben-Menachem E, Pellock JM, Shields WD. Vigabatrin: 2008 update. Epilepsia. 2009;50:163\u2013173.","journal-title":"Epilepsia"},{"key":"284_CR7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1535-7511.2009.01315.x","volume":"9","author":"GL Krauss","year":"2009","unstructured":"Krauss GL. Evaluating risks for vigabatrin treatment. Epilepsy Curr. 2009;9:125\u2013129.","journal-title":"Epilepsy Curr"},{"key":"284_CR8","first-page":"36","volume-title":"Acta Neurol Scand Suppl","author":"L Carmant","year":"2011","unstructured":"Carmant L. Vigabatrin therapy for infantile spasms: review of major trials in Europe, Canada, and the United States; and recommendations for dosing. Acta Neurol Scand Suppl. 2011:36\u201347."},{"key":"284_CR9","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1111\/j.1528-1167.2010.02657.x","volume":"51","author":"JM Pellock","year":"2010","unstructured":"Pellock JM, Hrachovy R, Shinnar S, Baram TZ, Bettis D, Dlugos DJ, et al. Infantile spasms: a U.S. consensus report. Epilepsia. 2010;51:2175\u20132189.","journal-title":"Epilepsia"},{"key":"284_CR10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1528-1157.2002.24501.x","volume":"43","author":"EA Lukyanetz","year":"2002","unstructured":"Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia. 2002;43:9\u201318.","journal-title":"Epilepsia"},{"key":"284_CR11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/11316250-000000000-00000","volume":"12","author":"A Verrotti","year":"2010","unstructured":"Verrotti A, D\u2019Adamo E, Parisi P, Chiarelli F, Curatolo P. Levetiracetam in childhood epilepsy. Paediatr Drugs. 2010;12:177\u2013186.","journal-title":"Paediatr Drugs"},{"key":"284_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2010.10.003","volume":"15","author":"G Ramantani","year":"2011","unstructured":"Ramantani G, Ikonomidou C, Walter B, Rating D, Dinger J. Levetiracetam: safety and efficacy in neonatal seizures. Eur J Pediatr Neurol. 2011;15:1\u20137.","journal-title":"Eur J Pediatr Neurol"},{"key":"284_CR13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.seizure.2012.05.010","volume":"21","author":"A McTaque","year":"2012","unstructured":"McTaque A, Kneen R, Kumar R, Spinty S, Appleton R. Intravenous levetiracetam in acute repitive seizures and status epilepticus in children: experience from a children\u2019s hospital. Seizure. 2012;21:529\u2013534.","journal-title":"Seizure"},{"key":"284_CR14","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1046\/j.1528-1157.2001.32101.x","volume":"42","author":"EH Kossoff","year":"2001","unstructured":"Kossoff EH, Bergey GK, Freeman JM, Vining EP. Levetiracetam psychosis in children with epilepsy. Epilepsia. 2001;42:1611\u20131613.","journal-title":"Epilepsia"},{"key":"284_CR15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.seizure.2006.12.006","volume":"16","author":"A Verrotti","year":"2007","unstructured":"Verrotti A, Coppola G, Manco R, Ciambra G, Iannetti P, Grosso S, et al. Levetiracetam monotherapy for children and adolescents with benign rolandic seizures. Seizure. 2007;16:271\u2013275.","journal-title":"Seizure"},{"key":"284_CR16","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.pediatrneurol.2003.09.007","volume":"30","author":"EC Reyes De Los","year":"2004","unstructured":"De Los Reyes EC, Sharp GB, Williams JP, Hale SE. Levetiracetam in the treatment of Lennox-Gastaut syndrome. Pediatr Neurol. 2004;30:254\u2013256.","journal-title":"Pediatr Neurol"},{"key":"284_CR17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1469-8749.2007.02009.x","volume":"50","author":"A Verrotti","year":"2008","unstructured":"Verrotti A, Cerminara C, Coppola G, Franzoni E, Parisi P, Iannetti P, et al. Levetiracetam in juvenile myoclonic epilepsy: long-term efficacy in newly diagnosed adolescents. Dev Med Child Neurol. 2008;50:29\u201332.","journal-title":"Dev Med Child Neurol"},{"key":"284_CR18","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.yebeh.2007.07.011","volume":"11","author":"EH Kossoff","year":"2007","unstructured":"Kossoff EH, Los JG, Boatman DF. A pilot study transitioning children onto levetiracetam monotherapy to improve language dysfunction associated with benign rolandic epilepsy. Epilepsy Behav. 2007;11:514\u2013517.","journal-title":"Epilepsy Behav"},{"key":"284_CR19","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1046\/j.1528-1157.2001.32101.x","volume":"42","author":"EH Kossoff","year":"2001","unstructured":"Kossoff EH, Bergey GK, Freeman JM, Vining EP. Levetiracetam psychosis in children with epilepsy. Epilepsia. 2001;42:1611\u20131613.","journal-title":"Epilepsia"},{"key":"284_CR20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0920-1211(00)00202-3","volume":"43","author":"G Coppola","year":"2001","unstructured":"Coppola G, Caliendo G, Terracciano MM, Buono S, Pellegrino L, Pascotto A. Topiramate in refractory partialonset seizures in children, adolescents and young adults: a multicentric open trial. Epilepsy Res. 2001;43:255\u2013260.","journal-title":"Epilepsy Res"},{"key":"284_CR21","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s12098-011-0395-z","volume":"78","author":"P Sreenivasan","year":"2011","unstructured":"Sreenivasan P, Kunju PA. Efficacy of Topiramate as an add-on drug in seizures in Indian children-an observational study. Indian J Pediatr. 2011;78:1221\u20131224.","journal-title":"Indian J Pediatr"},{"key":"284_CR22","first-page":"CD003277","volume":"2","author":"EC Hancock","year":"2013","unstructured":"Hancock EC, Cross JH. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev. 2013;2:CD003277.","journal-title":"Cochrane Database Syst Rev"},{"key":"284_CR23","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/WNF.0b013e3180986d43","volume":"31","author":"LP Zou","year":"2008","unstructured":"Zou LP, Lin Q, Qin J, Cai FC, Liu ZS, Mix E. Evaluation of open-label topiramate as primary or adjunctive therapy in infantile spasms. Clin Neuropharmacol. 2008;31:86\u201392.","journal-title":"Clin Neuropharmacol"},{"key":"284_CR24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0920-1211(03)00028-7","volume":"53","author":"Y Mikaeloff","year":"2003","unstructured":"Mikaeloff Y, de Saint-Martin A, Mancini J, Peudenier S, Pedespan JM, Vallee L, et al. Topiramate: efficacy and tolerability in children according to epilepsy syndromes. Epilepsy Res. 2003;53:225\u2013232.","journal-title":"Epilepsy Res"},{"key":"284_CR25","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1001\/archneur.62.11.1705","volume":"62","author":"V Biton","year":"2005","unstructured":"Biton V, Bourgeois BF. Topiramate in patients with juvenile myoclonic epilepsy. Arch Neurol. 2005;62:1705\u20131708.","journal-title":"Arch Neurol"},{"key":"284_CR26","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/08830738030180041001","volume":"18","author":"B Ben-Zeev","year":"2003","unstructured":"Ben-Zeev B, Watemberg N, Augarten A, Brand N, Yahav Y, Efrati O, et al. Oligohydrosis and hyperthermia: pilot study of a novel topiramate adverse effect. J Child Neurol. 2003;18:254\u2013257.","journal-title":"J Child Neurol"},{"key":"284_CR27","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/epi.12125","volume":"54","author":"Y Yamamoto","year":"2013","unstructured":"Yamamoto Y, Takahashi Y, Imai K, Mishima N, Yazawa R, Inoue K, et al. Risk factor for hyperammonemia in pediatric patients with epilepsy. Epilepsia 2013;54:983\u2013989.","journal-title":"Epilepsia"},{"key":"284_CR28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s13312-011-0025-x","volume":"48","author":"R Jain","year":"2011","unstructured":"Jain R, Mishra D, Juneja M. Add-on lamotrigine in pediatric epilepsy in India. Indian Pediatr. 2011;48:55\u201358.","journal-title":"Indian Pediatr"},{"key":"284_CR29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejpn.2012.10.006","volume":"17","author":"C Doege","year":"2013","unstructured":"Doege C, May TW, Siniatchkin M, von Spiczak S, Stephani U, Boor R. Myoclonic astatic epilepsy (Doose syndrome) \u2014 A lamotrigine responsive epilepsy? Eur J Paediatr Neurol. 2013;17:29\u201335.","journal-title":"Eur J Paediatr Neurol"},{"key":"284_CR30","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1468-3083.2010.03935.x","volume":"25","author":"C Ferr\u00e1ndiz-Pulido","year":"2011","unstructured":"Ferr\u00e1ndiz-Pulido C, Garc\u00eda-Fern\u00e1ndez D, Dom\u00ednguez-Sampedro P, Garc\u00eda-Patos V. Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of the experience with paediatric patients in a university hospital. J Eur Acad Dermatol Venereol. 2011;25:1153\u20131159.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"284_CR31","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1093\/brain\/aws151","volume":"135","author":"A Brunklaus","year":"2012","unstructured":"Brunklaus A, Ellis R, Reavey E, Forbes GH, Zuberi SM. Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome. Brain. 2012;135:2329\u20132336.","journal-title":"Brain"},{"key":"284_CR32","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/epi.12074","volume":"54","author":"T Glauser","year":"2013","unstructured":"Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kalviainen R, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54:551\u2013563.","journal-title":"Epilepsia"},{"key":"284_CR33","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1592\/phco.21.11.904.34513","volume":"21","author":"TA Glauser","year":"2001","unstructured":"Glauser TA. Oxcarbazepine in the treatment of epilepsy. Pharmacotherapy. 2001;21:904\u2013919.","journal-title":"Pharmacotherapy"},{"key":"284_CR34","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.braindev.2009.02.003","volume":"32","author":"YJ Lee","year":"2010","unstructured":"Lee YJ, Kang HC, Seo JH, Lee JS, Kim HD. Efficacy and tolerability of adjunctive therapy with zonisamide in childhood intractable epilepsy. Brain Dev. 2010;32:208\u2013212.","journal-title":"Brain Dev"},{"key":"284_CR35","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1177\/088307380502000101","volume":"20Suppl1","author":"JW Wheless","year":"2005","unstructured":"Wheless JW, Clarke DF, Carpenter D. Treatment of pediatric epilepsy: expert opinion, 2005. J Child Neurol. 2005;20 Suppl 1:S1\u2013S56.","journal-title":"J Child Neurol"},{"key":"284_CR36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1684\/epd.2008.0168","volume":"10","author":"DG Vossler","year":"2008","unstructured":"Vossler DG, Conry JA, Murphy JV. Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: an open-label study. Epileptic Disord. 2008;10:31\u201334.","journal-title":"Epileptic Disord"},{"key":"284_CR37","first-page":"169","volume":"3","author":"M Seino","year":"1991","unstructured":"Seino M, Miyazaki H, Ito T. Zonisamide. Epilepsy Res Suppl. 1991;3:169\u2013174.","journal-title":"Zonisamide. Epilepsy Res Suppl"},{"key":"284_CR38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.eplepsyres.2004.06.009","volume":"62","author":"PA Low","year":"2004","unstructured":"Low PA, James S, Peschel T, Leong R, Rothstein A. Zonisamide and associated oligohidrosis and hyperthermia. Epilepsy Res. 2004;62:27\u201334.","journal-title":"Epilepsy Res"},{"key":"284_CR39","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.seizure.2011.04.005","volume":"20","author":"SH Eun","year":"2011","unstructured":"Eun SH, Kim HD, Eun BL, Lee IK, Chung HG, Kim JS, et al. Compartive trial of low- and high-dose zonisamide as monotherapy for childhood epilepsy. Seizure. 2011;20:558\u2013563.","journal-title":"Seizure"},{"key":"284_CR40","first-page":"211","volume":"17","author":"ML Buck","year":"2012","unstructured":"Buck ML, Goodkin HP. Use of lacosamide in children with refractory epilepsy. J Pediatr Pharmacol Ther. 2012;17:211\u2013219.","journal-title":"J Pediatr Pharmacol Ther"},{"key":"284_CR41","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejpn.2011.08.007","volume":"16","author":"E Heyman","year":"2012","unstructured":"Heyman E, Lahat E, Levin N, Berkovitch M, Gandelman-Marton R. Preliminary efficacy and safety of lacosamide in children with refractory epilepsy. Eur J Paediatr Neurol. 2012;16:15\u201319.","journal-title":"Eur J Paediatr Neurol"},{"key":"284_CR42","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1177\/0883073812436741","volume":"27","author":"RG Rastogi","year":"2012","unstructured":"Rastogi RG, Ng YT. Lacosamide in refractory mixed pediatric epilepsy: a prospective add-on study. J Child Neurol. 2012;27:492\u2013495.","journal-title":"J Child Neurol"},{"key":"284_CR43","volume-title":"J Child Neurol","author":"WR Yorns Jr.","year":"2012","unstructured":"Yorns WR, Jr., Khurana DS, Carvalho KS, Hardison HH, Legido A, Valencia I. Efficacy of Lacosamide as adjunctive therapy in children with refractory epilepsy. J Child Neurol. 2012. Epub ahead of print."},{"key":"284_CR44","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2165\/11586920-000000000-00000","volume":"13","author":"HA Wier","year":"2011","unstructured":"Wier HA, Cerna A, So TY. Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. Paediatr Drugs. 2011;13:97\u2013106.","journal-title":"Paediatr Drugs"},{"key":"284_CR45","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1212\/01.wnl.0000303813.95800.0d","volume":"70","author":"T Glauser","year":"2008","unstructured":"Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008;70:1950\u20131958.","journal-title":"Neurology"},{"key":"284_CR46","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/1756285613481083","volume":"6","author":"DT Hsieh","year":"2013","unstructured":"Hsieh DT, Thiele EA. Efficacy and safety of rufinamide in pediatric epilepsy. Ther Adv Neurol Disord. 2013;6:189\u2013198.","journal-title":"Ther Adv Neurol Disord"},{"key":"284_CR47","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1468-1331.2010.03113.x","volume":"18","author":"G Coppola","year":"2011","unstructured":"Coppola G, Grosso S, Franzoni E, Veggiotti P, Zamponi N, Parisi P, et al. Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut syndrome. Eur J Neurol. 2011;18:246\u2013251.","journal-title":"Eur J Neurol"},{"key":"284_CR48","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.eplepsyres.2012.05.004","volume":"102","author":"R Moavero","year":"2012","unstructured":"Moavero R, Cusmai R, Specchio N, Fusco L, Capuano A, Curatolo P, et al. Rufinamide efficacy and safety as adjunctive treatment in children with focal drug resistant epilepsy: the first Italian prospective study. Epilepsy Res. 2012;102:94\u201399.","journal-title":"Epilepsy Res"},{"key":"284_CR49","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s40263-012-0004-3","volume":"26","author":"GL Plsker","year":"2012","unstructured":"Plsker GL. Stiripentol: in severe Myoclonic epilepsy of infancy (Dravet syndrome). CNS Drugs. 2012;26:993\u20131001.","journal-title":"CNS Drugs"},{"key":"284_CR50","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.neuropharm.2008.06.004","volume":"56","author":"JL Fisher","year":"2009","unstructured":"Fisher JL. The anti-convulsant stiripentol acts directly on the GABA(A) receptor as a positive allosteric modulator. Neuropharmacology. 2009;56:190\u2013197.","journal-title":"Neuropharmacology"},{"key":"284_CR51","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","volume":"356","author":"C Chiron","year":"2000","unstructured":"Chiron C, Marchand MC, Tran A, Rey E, d\u2019Athis P, Vincent J, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndromededicated trial. STICLO study group. Lancet. 2000;356:1638\u20131642.","journal-title":"Lancet"},{"key":"284_CR52","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1124\/mol.58.3.591","volume":"58","author":"AD Wickenden","year":"2000","unstructured":"Wickenden AD, Yu W, Zou A, Jegla T, Wagoner PK. Retigabine, a novel anti-convulsant, enhances activation of KCNQ2\/Q3 potassium channels. Mol Pharmacol. 2000;58:591\u2013600.","journal-title":"Mol Pharmacol"},{"key":"284_CR53","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.eplepsyres.2012.03.010","volume":"101","author":"RJ Porter","year":"2012","unstructured":"Porter RJ, Burdette DE, Gil-Nagel A, Hall ST, White R, Shaikh S, et al. Retigabine as adjunctive therapy in adults with partial-onset seizures: integrated analysis of three pivotal controlled trials. Epilepsy Res. 2012;101:103\u2013112.","journal-title":"Epilepsy Res"},{"key":"284_CR54","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.spen.2010.10.003","volume":"17","author":"CJ Chu-Shore","year":"2010","unstructured":"Chu-Shore CJ, Thiele EA. New drugs for pediatric epilepsy. Semin Pediatr Neurol. 2010;17:214\u2013223.","journal-title":"Semin Pediatr Neurol"},{"key":"284_CR55","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0920-1211(00)00170-4","volume":"42","author":"JF Kerrigan","year":"2000","unstructured":"Kerrigan JF, Shields WD, Nelson TY, Bluestone DL, Dodson WE, Bourgeois BF, et al. Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, addon trial. Epilepsy Res 2000;42:133\u2013139.","journal-title":"Epilepsy Res"},{"key":"284_CR56","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/11584860-000000000-00000","volume":"25","author":"LJ Stephen","year":"2011","unstructured":"Stephen LJ, Brodie MJ. Pharmacotherapy of epilepsy: newly approved and developmental agents. CNS Drugs. 2011;25:89\u2013107.","journal-title":"CNS Drugs"},{"key":"284_CR57","first-page":"681","volume":"46","author":"Expert Commitee on Pediatric Epilepsy, Indian Academy of Pediatrics.","year":"2009","unstructured":"Expert Commitee on Pediatric Epilepsy, Indian Academy of Pediatrics. Guidelines for diagnosis and management of childhood epilepsy. Indian Pediatr. 2009;46:681\u2013698.","journal-title":"Indian Pediatr"}],"container-title":["Indian Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13312-013-0284-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13312-013-0284-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13312-013-0284-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T15:47:42Z","timestamp":1716133662000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13312-013-0284-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":57,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["284"],"URL":"https:\/\/doi.org\/10.1007\/s13312-013-0284-9","relation":{},"ISSN":["0019-6061","0974-7559"],"issn-type":[{"value":"0019-6061","type":"print"},{"value":"0974-7559","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}